Wen Xu

6.8k total citations · 3 hit papers
157 papers, 4.2k citations indexed

About

Wen Xu is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Wen Xu has authored 157 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 47 papers in Molecular Biology and 24 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Wen Xu's work include Cancer Immunotherapy and Biomarkers (17 papers), Cancer-related Molecular Pathways (11 papers) and Immunotherapy and Immune Responses (9 papers). Wen Xu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Cancer-related Molecular Pathways (11 papers) and Immunotherapy and Immune Responses (9 papers). Wen Xu collaborates with scholars based in China, Australia and United States. Wen Xu's co-authors include Bin Li, Jing Yang, Miao Sun, Kui Sheng Chen, Yan He, Qing‐Yu He, Yuan‐Han Yang, Can‐Can Zheng, Yaping Liu and Ming‐Liang He and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Wen Xu

146 papers receiving 4.2k citations

Hit Papers

Targeting PI3K/Akt signal... 2020 2026 2022 2024 2021 2020 2021 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Targeting PI3K/Akt signal transduction for cancer therapy
    2021 1.0k citations Yan He, Miao Sun et al. Signal Transduction and Targeted Therapy profile →
  2. Advances in targeted therapy for esophageal cancer
    2020 324 citations Yuan‐Han Yang, Wen Xu et al. Signal Transduction and Targeted Therapy profile →
  3. Molecular mechanisms of chemo‐ and radiotherapy resistance and the potential implications for cancer treatment
    2021 231 citations Yaping Liu, Can‐Can Zheng et al. SHILAP Revista de lepidopterología profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wen Xu China 32 1.8k 1.1k 747 672 476 157 4.2k
Yan Luo China 40 2.3k 1.2× 765 0.7× 523 0.7× 413 0.6× 529 1.1× 201 6.2k
Xiaowei Qi China 33 1.9k 1.1× 835 0.8× 1.3k 1.7× 425 0.6× 313 0.7× 199 3.8k
Hua Guo China 38 2.4k 1.3× 816 0.7× 1.2k 1.6× 436 0.6× 571 1.2× 161 4.5k
Jie Gao China 43 2.9k 1.6× 882 0.8× 578 0.8× 558 0.8× 561 1.2× 238 6.4k
Lingli Chen China 32 1.5k 0.8× 772 0.7× 420 0.6× 621 0.9× 381 0.8× 103 4.0k
Xiaobing Liu China 28 2.2k 1.2× 869 0.8× 1.1k 1.5× 631 0.9× 419 0.9× 150 4.6k
Lin Chen China 39 3.2k 1.7× 1.3k 1.1× 1.2k 1.6× 845 1.3× 254 0.5× 270 5.9k
Jing Lü China 41 4.5k 2.5× 1.3k 1.2× 558 0.7× 397 0.6× 222 0.5× 189 6.8k
Yihan Wang China 36 2.1k 1.2× 564 0.5× 407 0.5× 409 0.6× 239 0.5× 191 4.2k
José Prados Spain 37 2.1k 1.1× 958 0.9× 565 0.8× 374 0.6× 330 0.7× 238 4.9k

Countries citing papers authored by Wen Xu

Since Specialization
Citations

This map shows the geographic impact of Wen Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wen Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wen Xu more than expected).

Fields of papers citing papers by Wen Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wen Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wen Xu. The network helps show where Wen Xu may publish in the future.

Co-authorship network of co-authors of Wen Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Wen Xu. A scholar is included among the top collaborators of Wen Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wen Xu. Wen Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xu, Wen, et al.. (2025). aac(6’)-Iaq, a novel aminoglycoside acetyltransferase gene identified from an animal isolate Brucella intermedia DW0551. Frontiers in Cellular and Infection Microbiology. 15. 1551240–1551240.
2.
3.
Xu, Wen, et al.. (2024). Clinical and Histopathological Investigation of Pediatric Melanonychia. Annals of Plastic Surgery. 92(4S). S87–S90.
4.
Xu, Wen, et al.. (2024). Serum ACTH and Cortisol Level is Associated with the Acute Gastrointestinal Injury Grade in ICU Patients. International Journal of General Medicine. Volume 17. 127–134. 1 indexed citations
5.
Xu, Wen, et al.. (2024). Genetic links between atopy, allergy, and alopecia areata: insights from a Mendelian randomization study. Allergy Asthma and Clinical Immunology. 20(1). 32–32. 3 indexed citations
6.
Mullally, William, et al.. (2023). EP08.02-03 Real World Experience of Survival Outcomes in Consolidative Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 18(11). S569–S569. 1 indexed citations
7.
Weppler, Alison M., Laetitia Da Meda, Inês Pires da Silva, et al.. (2023). Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. European Journal of Cancer. 183. 109–118. 14 indexed citations
8.
Shanker, Mihir, Victoria Atkinson, Wen Xu, et al.. (2022). Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes. Journal of Medical Imaging and Radiation Oncology. 66(4). 536–545. 8 indexed citations
9.
10.
He, Yan, Miao Sun, Jing Yang, et al.. (2021). Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduction and Targeted Therapy. 6(1). 425–425. 1019 indexed citations breakdown →
11.
Liu, Yaping, et al.. (2021). Molecular mechanisms of chemo‐ and radiotherapy resistance and the potential implications for cancer treatment. SHILAP Revista de lepidopterología. 2(3). 315–340. 231 indexed citations breakdown →
12.
Shenderov, Eugene, Piotr J. Wysocki, Wen Xu, et al.. (2021). 620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion. Annals of Oncology. 32. S657–S659. 21 indexed citations
13.
Huang, Xiaohui, Qihua Zhang, Hong Pan, et al.. (2020). Direct targeting of HSP90 with daurisoline destabilizes β-catenin to suppress lung cancer tumorigenesis. Cancer Letters. 489. 66–78. 42 indexed citations
14.
Owen, C., Xue Bai, Thuan Chong Quah, et al.. (2020). 1138P Delayed immune-related adverse events (irAEs) on anti-PD1-based therapy. Annals of Oncology. 31. S761–S762. 2 indexed citations
15.
Yang, Yuan‐Han, et al.. (2020). Advances in targeted therapy for esophageal cancer. Signal Transduction and Targeted Therapy. 5(1). 229–229. 324 indexed citations breakdown →
16.
Guo, Qie, Haijun Qu, Wen Xu, et al.. (2019). Ubenimex Reverses MDR in Gastric Cancer Cells by Activating Caspase-3-Mediated Apoptosis and Suppressing the Expression of Membrane Transport Proteins. BioMed Research International. 2019. 1–14. 17 indexed citations
17.
Li, Yue, Feng Xiong, Wen Xu, & Side Liu. (2019). Increased Serum Angiotensin II Is a Risk Factor of Nonalcoholic Fatty Liver Disease: A Prospective Pilot Study. Gastroenterology Research and Practice. 2019. 1–7. 11 indexed citations
18.
Xu, Wen, Jianqin Huang, Lisha Li, et al.. (2019). Alterations of estradiol-induced histone H3 acetylation in the preoptic area and anteroventral periventricular nucleus of middle-aged female rats. Biochemical and Biophysical Research Communications. 516(3). 894–899. 5 indexed citations
19.
20.
Hu, Huifang, Wen Xu, Yang Wang, et al.. (2017). Comparative Proteomics Analysis Identifies Cdc42-Cdc42BPA Signaling as Prognostic Biomarker and Therapeutic Target for Colon Cancer Invasion. Journal of Proteome Research. 17(1). 265–275. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yan Luo Breakdown of academic impact, for papers by Xiaowei Qi Breakdown of academic impact, for papers by Hua Guo Breakdown of academic impact, for papers by Jie Gao Breakdown of academic impact, for papers by Lingli Chen Breakdown of academic impact, for papers by Xiaobing Liu Breakdown of academic impact, for papers by Lin Chen Breakdown of academic impact, for papers by Jing Lü Breakdown of academic impact, for papers by Yihan Wang Breakdown of academic impact, for papers by José Prados
Rankless by CCL
2026